The global nuclear medicine radioisotopes market is poised for significant growth in the coming years, driven by advancements in diagnostic imaging and increasing demand for targeted cancer therapies. According to Expert Market Research, the market reached a valuation of USD 8.90 billion in 2024 and is projected to grow at a CAGR of 8.00% from 2025 to 2034, eventually reaching USD 19.21 billion by 2034. This growth is propelled by the rising incidence of chronic conditions like cancer and thyroid disorders, alongside improvements in healthcare infrastructure and diagnostic accuracy.

Nuclear Medicine Radioisotopes Market Share

North America leads the global nuclear medicine radioisotopes market, owing to its established healthcare system, high adoption of advanced diagnostic technologies, and robust research infrastructure. The U.S. in particular, is home to several key market players and accounts for the largest share in both diagnostic and therapeutic applications.

Europe follows, supported by increased government funding for nuclear medicine research and improved patient access to imaging technologies. Meanwhile, Asia Pacific is emerging as a high-growth region due to rising healthcare expenditures, increasing cancer prevalence, and growing awareness of early disease detection.

Among the various radioisotopes, Technetium-99m (Tc-99m) dominates the market, accounting for the largest share in diagnostic nuclear medicine procedures due to its favorable imaging characteristics and short half-life.

Nuclear Medicine Radioisotopes Market Growth & Trends

The market is experiencing transformative trends that are reshaping its trajectory:

  • Rising incidence of cancer and thyroid disorders has led to increased demand for radioisotope-based imaging and therapies.

  • Technological advancements in imaging modalities such as SPECT/CT and PET/CT are enhancing diagnostic precision and clinical decision-making.

  • Growing preference for targeted radionuclide therapies (TRTs) like Lutetium-177 and Actinium-225, which offer improved patient outcomes with minimal side effects.

  • Expansion of radiopharmaceutical production capabilities, particularly in emerging economies, is improving supply chain efficiency.

  • Emphasis on personalized medicine, where radiopharmaceuticals play a critical role in tailored diagnostics and treatments.

According to Wikipedia, nuclear medicine uses small amounts of radioactive materials to diagnose or treat a variety of diseases, including many types of cancers, heart disease, and other abnormalities within the body.

Nuclear Medicine Radioisotopes Market Case Studies & News

The industry has seen notable strategic developments in recent years:

  • In 2023, Cardinal Health expanded its nuclear manufacturing and distribution facilities across the U.S. to meet growing demand for radiopharmaceuticals.

  • NorthStar Medical Radioisotopes received FDA approval for its non-uranium-based production method for Mo-99, enhancing the sustainability of isotope supply.

  • Bayer AG and Curium have actively expanded their targeted alpha therapy pipelines, investing in Actinium-225-based compounds for oncology applications.

  • Siemens Healthineers and GE HealthCare have advanced their SPECT/PET systems with AI integration, improving the accuracy of scans and patient throughput.

These examples underscore the sector’s focus on innovation, capacity expansion, and patient-centered solutions.

Nuclear Medicine Radioisotopes Market Analysis

The market remains competitive with a mix of established players and emerging innovators. Key differentiators include:

  • Technological capabilities in radioisotope production

  • Vertical integration from isotope generation to diagnostic device manufacturing

  • Regulatory approvals and compliance with nuclear safety protocols

Regulatory frameworks in regions such as North America (via the NRC and FDA), Europe (through EMA), and Asia (notably Japan and India) play a critical role in the approval and adoption of nuclear medicine products. Additionally, investments in cyclotron and reactor infrastructure are influencing market dynamics globally.

Nuclear Medicine Radioisotopes Market Segmentation

By Radioisotope Type

  • Technetium-99m (Tc-99m) – Most widely used in diagnostics

  • Thallium-201 (Tl-201) – Applied in myocardial perfusion imaging

  • Iodine (I-123 & I-131) – Commonly used for thyroid diagnostics and therapy

  • Fluorine-18 – Key PET imaging isotope

  • Rubidium-82 (Rb-82) – Ideal for cardiac PET imaging

  • Lutetium-177 (Lu-177) – Gaining traction in cancer therapies

  • Radium-223 (Ra-223) and Alpharadin – Approved for metastatic prostate cancer

  • Actinium-225 (Ac-225) – Promising in alpha-emitter therapies

  • Others

By Application

  • Oncology – Largest segment due to increasing cancer cases

  • Cardiology – High use of SPECT tracers for cardiac assessments

  • Thyroid – Consistent demand for iodine-based isotopes

  • Neurology – Increasing PET use in Alzheimer's and Parkinson’s

  • Other Applications

By End User

  • Hospitals – Largest end-user due to integrated diagnostic services

  • Diagnostic Labs – Rapid growth due to rising outpatient imaging demand

  • Others – Includes academic and research institutes

By Region

  • North America

  • Europe

  • Asia Pacific

  • Latin America

  • Middle East and Africa

Each region presents unique growth opportunities depending on infrastructure maturity, disease burden, and access to radioisotope technology.

Nuclear Medicine Radioisotopes Market Key Players

The market is led by a blend of multinational corporations and regional specialists with robust R&D and production capabilities:

  • GE HealthCare

  • Cardinal Health

  • Curium

  • Bayer AG

  • Lantheus Holdings, Inc.

  • Bracco Imaging S.p.A.

  • PharmaLogic Holdings Corp.

  • Eczacibasi-Monrol Nuclear Products

  • Nordion Inc.

  • NorthStar Medical Radioisotopes

  • NTP Radioisotopes SOC Ltd

  • Aenorasis

  • Positron Corporation

  • Nordion Inc. (Sotera Health Company)

  • Siemens Healthineers

These players are actively engaged in expanding production capacities, advancing radioisotope research, and entering strategic partnerships to enhance their global footprint.

The nuclear medicine radioisotopes market is on a growth trajectory driven by a combination of rising disease burden, technological advancements, and growing adoption of molecular imaging. As demand for non-invasive and precise diagnostic tools continues to rise, radioisotopes will play a central role in modern healthcare diagnostics and therapies.

To explore comprehensive data, forecasts, and company profiles, refer to the full report by Expert Market Research.

Find More Report:

CDMO Market size

Treatment Resistant Depression Drug Pipeline Analysis share

Metastatic Castration-Resistant Prostate Cancer Drug Pipeline Analysis growth